Here, we have shown that 18-consecutive-week (equivalent to ~13 human years) treatment with GNE-7915 significantly reduced αSyn oligomer accumulation in mutant LRRK2 mouse striatum, a vulnerable brain region in PD. This evidence concerns the gene LRRK2 and Parkinson disease.